Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Arthritis, Rheumatoid 8Melanoma 6Colitis, Ulcerative 6Inflammatory Bowel Diseases 5Crohn Disease 5Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Colitis 3Urogenital Neoplasms 2Inflammation 2Hematologic Neoplasms 2Graft vs Host Disease 2Fatigue 2Depressive Disorder, Major 2Depression 2Cachexia 2Anorexia 2Vasculitis 1Takayasu Arteritis 1Syndrome 1Stroke 1Stevens-Johnson Syndrome 1Spondylitis, Ankylosing 1Skin Neoplasms 1Recurrence 1Rare Diseases 1Psoriasis 1Precancerous Conditions 1Pemphigoid, Benign Mucous Membrane 1Pancreatic Neoplasms 1

Interventions

Escitalopram 3Psilocybin 2Interpersonal Psychotherapy 2Infliximab 2Antidepressive Agents 2abacavir 1Vortioxetine 1Venlafaxine Hydrochloride 1Transcranial Magnetic Stimulation 1Sugars 1Saline Solution 1Mirtazapine 1Magnetic Resonance Spectroscopy 1Ketamine 1Fatty Acids, Omega-3 1Diagnostic Imaging 1Desvenlafaxine Succinate 1Cognitive Behavioral Therapy 1Citalopram 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Depressive Disorder, Major × Infliximab × Clear all
NCT00463580 2025-07-08

Infliximab

Emory University

Phase 4 Completed
60 enrolled 15 charts

Bipolar Disorder, Depression, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant

NCT06136546 2025-05-07

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

Massachusetts General Hospital

Phase 2 Recruiting
100 enrolled

Depression, Depressive Disorder, Major, Inflammation, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡